How much does a box of imatinib cost?

Imatinib (Imatinib) is a targeted drug used to treat many types of cancer, especially chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). It is a tyrosine kinase inhibitor that acts on BCR-ABL tyrosine kinase, an abnormal protein formed due to chromosomal translocation and found in most CML patients. Imatinib blocks the growth and spread of cancer cells by inhibiting the activity of this kinase, thereby effectively controlling the progression of the disease.

Imatinib is currently on the market in China and has been included in medical insurance. The price of 100mg*60 tablets is around 600 to 700. For specific prices and medical insurance reimbursement, please consult the local hospital pharmacy. The cheaper ones abroad are Indian generic drugs. The specifications of 100mg*120 tablets are about three to four hundred, which are the same as domestic generic drugs.

Imatinib was first approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of CML and has since been widely used in many countries around the world. Its mechanism of action is based on selectively targeting the growth signaling pathways of cancer cells, with high specificity and therefore relatively few side effects. Common side effects include nausea, fatigue, edema, and muscle cramps, but are tolerated by most patients.

In addition toCML, imatinib is also used to treat a number of other cancers with similar tyrosine kinase mutations, including gastrointestinal stromal tumors and certain types of skin cancer. The introduction of imatinib has significantly changed the treatment model of these cancers, especially in the treatment of CML, which has greatly extended the survival time of many patients and effectively delayed the progression of the disease.

Due to the wide application of imatinib, its market price has attracted global attention. Prices vary significantly between countries and regions, and as patents expire, the emergence of generic drugs also causes prices to drop. However, drug costs remain high in some regions, especially in countries without robust health insurance systems. Overall, imatinib offers new hope to many patients and has become a landmark drug in the field of targeted cancer therapy.